Tiantian vaccinia HIV vaccine
Status:Completed
Phase:I
Principal Investigator(s):Yiming Shao
Objective:To evaluate DNA replicating vaccinia Tiantan (rTV) expressing HIV CN54 gag, pol and env genes.last updated March 30, 2021
Prevention Option(s):HIV Vaccine
Study Design:
Arms and Assigned Interventions
Description
Mode of DeliveryRing, Spray, Subcutaneous
ARMsExperimental
Trial Sponsors:
Changchun BCHD, Chinese Center for Disease Control and Prevention, Guangxi CDC
Start Date
End Date
November 1, 2007
none
Enrollment:48
Age range:
18 Years ↔
50 Years
Population:Cisgender Men, Cisgender Women